Relpax Patent Fight Revived After Stalled Settlement

Law360, New York (October 4, 2011, 10:15 PM EDT) -- A New York federal judge on Tuesday reopened Pfizer Inc.'s patent infringement suit against Apotex Inc. over the company's plan to sell a generic version of the migraine drug Relpax, after a proposed settlement fell through.

The companies told the court in July that they were close to a settlement, but the settlement “[had] not yet been consummated,” Pfizer said in a notice issued Sept. 7 and signed by U.S. District Judge Lewis A. Kaplan on Tuesday.

Pfizer filed suit in July 2010, after Toronto-based Apotex,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.